JP2014513954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513954A5 JP2014513954A5 JP2014506595A JP2014506595A JP2014513954A5 JP 2014513954 A5 JP2014513954 A5 JP 2014513954A5 JP 2014506595 A JP2014506595 A JP 2014506595A JP 2014506595 A JP2014506595 A JP 2014506595A JP 2014513954 A5 JP2014513954 A5 JP 2014513954A5
- Authority
- JP
- Japan
- Prior art keywords
- wing segment
- linked nucleosides
- modified oligonucleotide
- sugar
- stranded modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002777 nucleoside Substances 0.000 claims 46
- 125000003835 nucleoside group Chemical group 0.000 claims 36
- 108091034117 Oligonucleotide Proteins 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 26
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 18
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 10
- 229940104302 cytosine Drugs 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000008266 deoxy sugars Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478038P | 2011-04-21 | 2011-04-21 | |
| US201161478040P | 2011-04-21 | 2011-04-21 | |
| US61/478,040 | 2011-04-21 | ||
| US61/478,038 | 2011-04-21 | ||
| US201261596690P | 2012-02-08 | 2012-02-08 | |
| US201261596692P | 2012-02-08 | 2012-02-08 | |
| US61/596,692 | 2012-02-08 | ||
| US61/596,690 | 2012-02-08 | ||
| PCT/US2012/034550 WO2012145697A1 (en) | 2011-04-21 | 2012-04-20 | Modulation of hepatitis b virus (hbv) expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016219348A Division JP6426678B2 (ja) | 2011-04-21 | 2016-11-10 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513954A JP2014513954A (ja) | 2014-06-19 |
| JP2014513954A5 true JP2014513954A5 (OSRAM) | 2015-05-14 |
| JP6042871B2 JP6042871B2 (ja) | 2016-12-14 |
Family
ID=47041953
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506595A Active JP6042871B2 (ja) | 2011-04-21 | 2012-04-20 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| JP2016219348A Active JP6426678B2 (ja) | 2011-04-21 | 2016-11-10 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| JP2018199169A Active JP6743106B2 (ja) | 2011-04-21 | 2018-10-23 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016219348A Active JP6426678B2 (ja) | 2011-04-21 | 2016-11-10 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| JP2018199169A Active JP6743106B2 (ja) | 2011-04-21 | 2018-10-23 | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | US8642752B2 (OSRAM) |
| EP (4) | EP3505528B1 (OSRAM) |
| JP (3) | JP6042871B2 (OSRAM) |
| KR (3) | KR102055331B1 (OSRAM) |
| CN (3) | CN106191060B (OSRAM) |
| AU (1) | AU2012245243B2 (OSRAM) |
| CA (1) | CA2833766C (OSRAM) |
| CL (1) | CL2013003053A1 (OSRAM) |
| CO (1) | CO6862103A2 (OSRAM) |
| CR (2) | CR20190207A (OSRAM) |
| CY (1) | CY1124327T1 (OSRAM) |
| DK (1) | DK3505528T3 (OSRAM) |
| DO (1) | DOP2013000246A (OSRAM) |
| EA (1) | EA029137B1 (OSRAM) |
| ES (1) | ES2856266T3 (OSRAM) |
| HR (1) | HRP20210244T1 (OSRAM) |
| HU (1) | HUE053401T2 (OSRAM) |
| IL (2) | IL228874B (OSRAM) |
| LT (1) | LT3505528T (OSRAM) |
| MX (2) | MX340408B (OSRAM) |
| MY (1) | MY169474A (OSRAM) |
| NZ (2) | NZ705820A (OSRAM) |
| PE (2) | PE20181267A1 (OSRAM) |
| PH (2) | PH12019502377A1 (OSRAM) |
| PL (1) | PL3505528T3 (OSRAM) |
| PT (1) | PT3505528T (OSRAM) |
| RS (1) | RS61447B1 (OSRAM) |
| RU (1) | RU2667524C2 (OSRAM) |
| SG (2) | SG10201604074TA (OSRAM) |
| SI (1) | SI3505528T1 (OSRAM) |
| SM (1) | SMT202100084T1 (OSRAM) |
| TW (1) | TWI548745B (OSRAM) |
| UA (1) | UA118951C2 (OSRAM) |
| WO (1) | WO2012145697A1 (OSRAM) |
| ZA (1) | ZA201307620B (OSRAM) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| CA2667055C (en) | 2006-10-18 | 2017-05-09 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| LT2496691T (lt) | 2009-11-02 | 2017-06-12 | University Of Washington | Terapinės nukleazės kompozicijos ir būdai |
| LT2606134T (lt) * | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| HRP20180564T1 (hr) | 2011-04-29 | 2018-06-01 | University of Washington, UW Center for Commercialization | Terapijski pripravci nukleaze i postupci |
| KR102434346B1 (ko) | 2011-06-30 | 2022-08-18 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| RU2679130C2 (ru) | 2012-07-11 | 2019-02-06 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| CA2883785C (en) | 2012-08-30 | 2020-08-18 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
| US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| DK2906696T4 (da) | 2012-10-15 | 2023-02-27 | Ionis Pharmaceuticals Inc | Fremgangsmåder til modulering af c9orf72-ekspression |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| WO2014062691A2 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| US20150291958A1 (en) | 2012-11-15 | 2015-10-15 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| US20150368642A1 (en) | 2013-01-30 | 2015-12-24 | Hoffmann-La Roche Inc. | Lna oligonucleotide carbohydrate conjugates |
| US9127276B2 (en) | 2013-05-01 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| EP3055414A4 (en) | 2013-10-11 | 2017-07-19 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| EP3063275B1 (en) | 2013-10-31 | 2019-09-25 | Resolve Therapeutics, LLC | Therapeutic nuclease-albumin fusions and methods |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| SI3126499T1 (sl) * | 2014-04-01 | 2020-09-30 | Biogen Ma Inc. | Sestave za moduliranje izražanja SOD-1 |
| PH12016502062B1 (en) | 2014-05-01 | 2023-01-27 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating complement factor b expression |
| CN106255755B (zh) | 2014-05-01 | 2020-07-24 | Ionis制药公司 | 用于调节血管生成素样蛋白3表达的组合物和方法 |
| GB201408623D0 (en) * | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
| JOP20200092A1 (ar) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| EA039127B1 (ru) * | 2015-03-24 | 2021-12-08 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| MY181815A (en) * | 2015-04-16 | 2021-01-08 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017015175A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| EP3332007A4 (en) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | RNAi Therapy Against Infection with Hepatitis B Virus |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| CN113952353A (zh) | 2015-11-06 | 2022-01-21 | Ionis制药公司 | 调节载脂蛋白(a)表达 |
| KR102515329B1 (ko) | 2016-03-07 | 2023-03-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
| HUE053172T2 (hu) | 2016-03-14 | 2021-06-28 | Hoffmann La Roche | Oligonukleotidok a PD-L1 expresszió csökkentésére |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| KR102627418B1 (ko) | 2016-09-14 | 2024-01-19 | 얀센 바이오파마, 인크. | 변형된 올리고뉴클레오티드 및 사용 방법 |
| KR20190065341A (ko) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | 올리고머 화합물들의 접합 방법 |
| KR20190076050A (ko) * | 2016-11-11 | 2019-07-01 | 얀센 바이오파마, 인크. | Hbv cccdna용 올리고뉴클레오티드 표적화 방법 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| CN110392581A (zh) * | 2016-12-13 | 2019-10-29 | 阿姆科学有限公司 | 用于预防或治疗乙型肝炎的药物组合物 |
| BR112019012057A2 (pt) | 2016-12-15 | 2019-11-12 | Meharry Medical College | agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv) |
| CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
| CN106701763B (zh) * | 2016-12-30 | 2019-07-19 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9靶向敲除人乙肝病毒P基因及其特异性gRNA |
| CN106916905B (zh) * | 2017-01-17 | 2018-06-08 | 重庆医科大学附属儿童医院 | 隐匿性乙肝病毒检测试剂盒及其检测方法 |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| CA3059446A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| MX2020002070A (es) | 2017-08-22 | 2020-03-24 | Sanabio Llc | Receptores solubles de interferon y usos de los mismos. |
| WO2019043193A1 (en) * | 2017-09-01 | 2019-03-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | INHIBITOR FOR USE IN THE PREVENTION AND / OR TREATMENT OF HEPATITIS B VIRUS INFECTION |
| CN118048356A (zh) | 2017-10-16 | 2024-05-17 | 豪夫迈·罗氏有限公司 | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 |
| SG11202003488WA (en) * | 2017-10-20 | 2020-05-28 | Dicerna Pharmaceuticals Inc | Methods for treating hepatitis b infection |
| WO2019157531A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| MA52661A (fr) | 2018-04-05 | 2021-02-17 | Centre Leon Berard | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b |
| PE20210346A1 (es) | 2018-07-03 | 2021-02-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau |
| AU2019300324A1 (en) | 2018-07-13 | 2021-01-21 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating RTEL1 expression |
| EP3837366A1 (en) | 2018-08-13 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof |
| CN109234275A (zh) * | 2018-08-30 | 2019-01-18 | 山东省立医院 | 一种可以同时抑制乙肝病毒dna和乙肝表面抗原的反义核苷酸 |
| JP2022524007A (ja) * | 2019-03-05 | 2022-04-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｂ型肝炎免疫化レジメンおよび組成物 |
| MX2021012098A (es) * | 2019-04-03 | 2021-11-03 | Bristol Myers Squibb Co | Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos. |
| CA3141874A1 (en) * | 2019-05-31 | 2020-12-03 | Aligos Therapeutics, Inc. | Modified gapmer oligonucleotides and methods of use |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| JP7653997B2 (ja) | 2019-12-19 | 2025-03-31 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| JP2023506954A (ja) | 2019-12-19 | 2023-02-20 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用 |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| WO2021226019A2 (en) * | 2020-05-04 | 2021-11-11 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
| US20220056451A1 (en) * | 2020-07-27 | 2022-02-24 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| CN116157522A (zh) | 2020-08-21 | 2023-05-23 | 豪夫迈·罗氏有限公司 | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2022240795A1 (en) * | 2021-05-10 | 2022-11-17 | Q-State Biosciences, Inc. | Compositions targeting sodium channel 1.6 |
| CA3235672A1 (en) * | 2021-11-29 | 2023-06-01 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein |
| JP2024546993A (ja) | 2021-12-17 | 2024-12-26 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ |
| CN119095963A (zh) * | 2022-01-10 | 2024-12-06 | 杭州浩博医药有限公司 | 乙型肝炎病毒(hbv)表达的调节 |
| KR20240144245A (ko) | 2022-01-28 | 2024-10-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | B형 간염 바이러스 감염을 치료하기 위한 조합 요법 |
| CA3246695A1 (en) | 2022-03-29 | 2023-10-05 | Glaxosmithkline Intellectual Property Development Limited | METHOD OF TREATMENT FOR CHRONIC HEPATITIS B |
| WO2024214041A1 (en) | 2023-04-12 | 2024-10-17 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating chronic hepatitis b |
| WO2025031485A1 (zh) * | 2023-08-10 | 2025-02-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制HBV基因表达的dsRNA分子及其应用 |
| CN118667808B (zh) * | 2023-08-22 | 2025-04-18 | 浙江柏拉阿图医药科技有限公司 | 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| CN119265194A (zh) * | 2023-09-21 | 2025-01-07 | 华辉安健（北京）生物科技有限公司 | 用于hbv相关疾病的化合物及其应用 |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
| CN119799705B (zh) * | 2024-07-08 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向调控HBV基因表达的siRNA及其应用 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5780219A (en) | 1989-07-11 | 1998-07-14 | Gen-Probe Incorporated | Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus |
| GB9006924D0 (en) | 1990-03-28 | 1990-05-23 | Imperial College | Prognosis of hepatitis infection |
| US5610050A (en) | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
| AU656136B2 (en) | 1990-04-20 | 1995-01-27 | General Hospital Corporation, The | Methods of preventing viral replication |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| EP0541693B1 (en) * | 1990-07-27 | 1998-12-09 | Chiron Corporation | Large comb-type branched polynucleotides |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO1993013120A1 (en) | 1991-12-23 | 1993-07-08 | Chiron Corporation | Hbv amplifier probes for use in solution phase sandwich hybridization assays |
| US6017756A (en) | 1992-05-14 | 2000-01-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting hepatitis B virus replication |
| US20030068301A1 (en) * | 1992-05-14 | 2003-04-10 | Kenneth Draper | Method and reagent for inhibiting hepatitis B virus replication |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
| US5736334A (en) | 1993-04-12 | 1998-04-07 | Abbott Laboratories | Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA |
| CA2167056A1 (en) | 1993-07-13 | 1995-01-26 | Uwe Spies | Nucleotide sequences and process for amplifying and detection of hepatitis b virus |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| JPH09507062A (ja) * | 1993-12-23 | 1997-07-15 | アポロン インク． | 抗ｂ型肝炎ウイルスオリゴヌクレオチド |
| US5728518A (en) | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5856459A (en) * | 1995-06-06 | 1999-01-05 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US6217858B1 (en) | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| ZA973367B (en) | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| CN1081069C (zh) * | 1998-08-14 | 2002-03-20 | 饶纬华 | 乙型肝炎治疗性疫苗及其制备方法 |
| JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ／エス | Ｌ−リボ−ｌｎａ類縁体 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
| JP2004512810A (ja) | 1999-08-31 | 2004-04-30 | サーナ・セラピューティクス・インコーポレイテッド | 核酸に基づく遺伝子発現の調節剤 |
| WO2001038498A2 (en) | 1999-11-24 | 2001-05-31 | Pharmasset, Ltd. | A new genotype of hepatitis b virus |
| JP2003515327A (ja) | 1999-12-03 | 2003-05-07 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Ｈｂｖ配列 |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP1152063A1 (en) | 2000-05-03 | 2001-11-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Method of diagnosing HBV infection stages |
| WO2002000613A2 (en) | 2000-06-27 | 2002-01-03 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| EP1383782A1 (en) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US20080161256A1 (en) | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| WO2003004602A2 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| US20030143527A1 (en) | 2001-10-09 | 2003-07-31 | Venkatakrishna Shyamala | Identification of oligonucleotides for the capture, detection and quantitation of hepatitis B viral DNA |
| WO2003033657A2 (en) | 2001-10-16 | 2003-04-24 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssrna viral infection |
| US20050266422A1 (en) | 2002-02-20 | 2005-12-01 | Sirna Therapeutics, Inc. | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides |
| EP2455390A1 (en) | 2002-04-12 | 2012-05-23 | Melbourne Health | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
| US7015317B2 (en) | 2002-05-02 | 2006-03-21 | Abbott Laboratories | Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids |
| EP1513958B1 (en) | 2002-06-14 | 2011-08-10 | Gen-Probe Incorporated | Compositions for detecting hepatitis b virus |
| US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2004024095A2 (en) | 2002-09-13 | 2004-03-25 | Idenix (Cayman) Limited | ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
| WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| CA2517235A1 (en) | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | Methods and constructs for evaluation of rnai targets and effector molecules |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US20040191776A1 (en) | 2003-03-21 | 2004-09-30 | Pei-Jer Chen | Method for genotyping and quantifying Hepatitis B Virus |
| US20040185452A1 (en) | 2003-03-21 | 2004-09-23 | Pei-Jer Chen | Identification of single nucleotide polymorphisms |
| US7067249B2 (en) | 2003-05-19 | 2006-06-27 | The University Of Hong Kong | Inhibition of hepatitis B virus (HBV) replication by RNA interference |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| CA3040025C (en) | 2003-06-12 | 2023-01-10 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP1493822A1 (de) | 2003-07-02 | 2005-01-05 | Labor Becker, Olgemoeller & Kollegen GbR | Detektionsverfahren für Nucleinsäuren mit interner Amplifikationskontrolle |
| KR100647277B1 (ko) | 2003-08-14 | 2006-11-17 | 삼성전자주식회사 | Ｂ형 간염 검사용 ｐｃｒ 프라이머 세트 및 이를 포함하는 ｂ형 간염 검사 키트 |
| WO2005021800A2 (en) | 2003-08-22 | 2005-03-10 | Sirna Therapeutics, Inc. | Detection and quantitation of nucleic acid molecules in biological samples |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| US20080207539A1 (en) | 2003-09-01 | 2008-08-28 | Patrick Arbuthnot | Self-Processing Rna Expression Cassette |
| EP1709178A4 (en) | 2003-12-16 | 2008-01-09 | Agency Science Tech & Res | METHODS AND COMPOUNDS FOR MODIFYING MICROBIAL CONTAMINATION DEGREE OF HEPATITIS VIRUS |
| EP1544311B1 (en) | 2003-12-16 | 2009-11-18 | Bio-Rad Pasteur | Oligonucleotides for the detection of hepatitis B virus |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| WO2006088490A2 (en) * | 2004-06-30 | 2006-08-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
| WO2006034545A1 (en) | 2004-09-28 | 2006-04-06 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
| WO2006039739A1 (en) | 2004-10-13 | 2006-04-20 | Melbourne Health | Hepatitis b viral (hbv) mutants detection and application |
| AU2005319306B9 (en) | 2004-12-22 | 2012-04-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP1696040A1 (en) | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
| US8182992B2 (en) | 2005-03-03 | 2012-05-22 | Ibis Biosciences, Inc. | Compositions for use in identification of adventitious viruses |
| US20080096839A1 (en) | 2005-03-09 | 2008-04-24 | Mogam Biotechnology Research Institute | Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same |
| US20060258610A1 (en) * | 2005-05-12 | 2006-11-16 | Isis Pharmaceuticals, Inc. | Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness |
| GB0519169D0 (en) | 2005-09-21 | 2005-10-26 | Leuven K U Res & Dev | Novel anti-viral strategy |
| GB0522578D0 (en) | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
| WO2007078029A1 (en) | 2006-01-05 | 2007-07-12 | Catch By Gene Co., Ltd. | A quantitative method for hbv-dna, a primer and probe for detecting hbv-dna, and a detecting kit comprising the same |
| WO2007084567A2 (en) | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
| WO2007089611A2 (en) | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals Inc. | Compositions and their uses directed to huntingtin |
| US7399845B2 (en) | 2006-01-27 | 2008-07-15 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| CN101490074B (zh) | 2006-05-11 | 2013-06-26 | Isis制药公司 | 5’-修饰的双环核酸类似物 |
| WO2008011473A2 (en) * | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
| DE602006008150D1 (de) | 2006-10-12 | 2009-09-10 | Bio Rad Pasteur | Doppelsträngige Sonden zur Fluoreszenzdetektion von Nukleinsäuren |
| CA2667055C (en) * | 2006-10-18 | 2017-05-09 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| CA2673622A1 (en) | 2006-12-22 | 2008-07-03 | Imuthes Limited | Lipid |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| US8232257B2 (en) | 2007-03-27 | 2012-07-31 | University Of Iowa Research Foundation | RNA interference mediated inactivation of hepatitis B virus in a subject |
| WO2008146251A2 (en) | 2007-05-29 | 2008-12-04 | University Of The Witwatersrand, Johannesburg | A primary micro rna expression cassette |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| ATE538127T1 (de) | 2007-07-05 | 2012-01-15 | Isis Pharmaceuticals Inc | 6-disubstituierte bicyclische nukleinsäureanaloga |
| US9434997B2 (en) | 2007-08-24 | 2016-09-06 | Lawrence Livermore National Security, Llc | Methods, compounds and systems for detecting a microorganism in a sample |
| WO2009038266A1 (en) | 2007-09-17 | 2009-03-26 | Mogam Biotechnology Research Institute | Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
| EP2205617A4 (en) | 2007-11-06 | 2013-10-16 | Siemens Healthcare Diagnostics | HEPATITIS B-VIRUS-SPECIFIC OLIGONUCLEOTIDE SEQUENCES |
| EP2225376B1 (en) * | 2007-12-03 | 2014-01-08 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pik3ca expression |
| EP2242846A1 (en) * | 2008-02-13 | 2010-10-27 | DSM IP Assets B.V. | Process for the production of a peptide |
| CN101565756B (zh) | 2008-04-25 | 2013-07-10 | 中山大学达安基因股份有限公司 | 一种乙型肝炎病毒核苷类似物耐药相关突变检测试剂盒 |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| US20100015708A1 (en) | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| US8293474B2 (en) | 2008-07-02 | 2012-10-23 | National Health Research Institutes | Oligonucleotides and use thereof for determining deletion in HBV Pre-S region |
| CN102083983B (zh) | 2008-08-01 | 2014-04-16 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
| EP3335715A3 (en) | 2008-10-15 | 2018-08-08 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
| US20100211327A1 (en) | 2009-02-03 | 2010-08-19 | Prosetta Bioconformatics, Inc. | Methods and Systems for Viral Diagnosis |
| US8815514B2 (en) | 2009-07-02 | 2014-08-26 | Co-Diagnostics, Inc. | Detection primers for nucleic acid extension or amplification reactions |
| JP5892938B2 (ja) | 2009-10-16 | 2016-03-30 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｈｂｖアンチセンス阻害剤 |
| US9410189B2 (en) | 2010-04-30 | 2016-08-09 | Co-Diagnostics, Inc. | Methods of preventing non-specific reactions of nucleotide sequences |
| US20130137090A1 (en) | 2010-07-06 | 2013-05-30 | Aptateck Bio Ltd. | Nucleic acid aptamer-based diagnostic methods with novel techniques for signal enhancement |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| WO2012045894A1 (es) | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
| KR20180110186A (ko) | 2010-10-28 | 2018-10-08 | 베니텍 바이오파마 리미티드 | Hbv 치료 |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US20120295961A1 (en) | 2011-04-21 | 2012-11-22 | Swayze Eric E | Modulation of hepatitis b virus (hbv) expression |
| KR102434346B1 (ko) | 2011-06-30 | 2022-08-18 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US11511972B1 (en) | 2019-09-26 | 2022-11-29 | Versatile, Inc. | System for tracking lifting events at a construction site |
-
2012
- 2012-04-20 EP EP19155538.2A patent/EP3505528B1/en active Active
- 2012-04-20 MY MYPI2013701973A patent/MY169474A/en unknown
- 2012-04-20 SG SG10201604074TA patent/SG10201604074TA/en unknown
- 2012-04-20 NZ NZ705820A patent/NZ705820A/en unknown
- 2012-04-20 KR KR1020137030465A patent/KR102055331B1/ko active Active
- 2012-04-20 SM SM20210084T patent/SMT202100084T1/it unknown
- 2012-04-20 US US13/452,703 patent/US8642752B2/en active Active
- 2012-04-20 NZ NZ616512A patent/NZ616512A/en unknown
- 2012-04-20 PE PE2018000483A patent/PE20181267A1/es unknown
- 2012-04-20 KR KR1020207026891A patent/KR20200110822A/ko not_active Ceased
- 2012-04-20 MX MX2013012196A patent/MX340408B/es active IP Right Grant
- 2012-04-20 PL PL19155538T patent/PL3505528T3/pl unknown
- 2012-04-20 CR CR20190207A patent/CR20190207A/es unknown
- 2012-04-20 WO PCT/US2012/034550 patent/WO2012145697A1/en not_active Ceased
- 2012-04-20 MX MX2016004337A patent/MX347253B/es unknown
- 2012-04-20 UA UAA201313518A patent/UA118951C2/uk unknown
- 2012-04-20 CN CN201610555441.7A patent/CN106191060B/zh active Active
- 2012-04-20 LT LTEP19155538.2T patent/LT3505528T/lt unknown
- 2012-04-20 CN CN201280025777.2A patent/CN103582648B/zh active Active
- 2012-04-20 EP EP20209058.5A patent/EP3816288A3/en active Pending
- 2012-04-20 PH PH1/2019/502377A patent/PH12019502377A1/en unknown
- 2012-04-20 PT PT191555382T patent/PT3505528T/pt unknown
- 2012-04-20 TW TW101114260A patent/TWI548745B/zh active
- 2012-04-20 EA EA201391572A patent/EA029137B1/ru unknown
- 2012-04-20 RS RS20210190A patent/RS61447B1/sr unknown
- 2012-04-20 SI SI201231882T patent/SI3505528T1/sl unknown
- 2012-04-20 DK DK19155538.2T patent/DK3505528T3/da active
- 2012-04-20 CA CA2833766A patent/CA2833766C/en active Active
- 2012-04-20 RU RU2013151843A patent/RU2667524C2/ru not_active Application Discontinuation
- 2012-04-20 CN CN202010047402.2A patent/CN111172162A/zh active Pending
- 2012-04-20 AU AU2012245243A patent/AU2012245243B2/en active Active
- 2012-04-20 HU HUE19155538A patent/HUE053401T2/hu unknown
- 2012-04-20 EP EP17186598.3A patent/EP3312189A1/en not_active Withdrawn
- 2012-04-20 JP JP2014506595A patent/JP6042871B2/ja active Active
- 2012-04-20 KR KR1020197036206A patent/KR102247463B1/ko active Active
- 2012-04-20 PE PE2013002380A patent/PE20141177A1/es active IP Right Grant
- 2012-04-20 EP EP12773736.9A patent/EP2699583A4/en not_active Withdrawn
- 2012-04-20 SG SG2013078043A patent/SG194555A1/en unknown
- 2012-04-20 ES ES19155538T patent/ES2856266T3/es active Active
-
2013
- 2013-10-14 ZA ZA2013/07620A patent/ZA201307620B/en unknown
- 2013-10-14 IL IL228874A patent/IL228874B/en active IP Right Grant
- 2013-10-17 PH PH12013502157A patent/PH12013502157A1/en unknown
- 2013-10-21 CL CL2013003053A patent/CL2013003053A1/es unknown
- 2013-10-21 DO DO2013000246A patent/DOP2013000246A/es unknown
- 2013-10-28 CR CR20130551A patent/CR20130551A/es unknown
- 2013-11-19 CO CO13271891A patent/CO6862103A2/es active IP Right Grant
- 2013-12-20 US US14/137,111 patent/US9034841B2/en active Active
-
2014
- 2014-08-20 US US14/464,449 patent/US9127278B2/en active Active
-
2015
- 2015-07-07 US US14/793,622 patent/US9677076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219348A patent/JP6426678B2/ja active Active
-
2017
- 2017-05-05 US US15/587,668 patent/US20170369883A1/en not_active Abandoned
-
2018
- 2018-10-23 JP JP2018199169A patent/JP6743106B2/ja active Active
-
2019
- 2019-07-25 IL IL268257A patent/IL268257A/en unknown
- 2019-07-25 US US16/522,490 patent/US20200190520A1/en not_active Abandoned
-
2021
- 2021-02-11 HR HRP20210244TT patent/HRP20210244T1/hr unknown
- 2021-02-16 CY CY20211100131T patent/CY1124327T1/el unknown
- 2021-07-30 US US17/389,599 patent/US20220064650A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513954A5 (OSRAM) | ||
| HRP20210244T1 (hr) | Moduliranje eksprimiranja virusa hepatitisa b (hbv) | |
| JP2014530004A5 (OSRAM) | ||
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| JP2015501155A5 (OSRAM) | ||
| IL264288A (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| JP2013516489A5 (OSRAM) | ||
| JP2014511686A5 (OSRAM) | ||
| JP2016116520A5 (OSRAM) | ||
| JP2015536132A5 (OSRAM) | ||
| JP2018199700A5 (OSRAM) | ||
| JP2016501513A5 (OSRAM) | ||
| JP2014521310A5 (OSRAM) | ||
| JP2017535610A5 (OSRAM) | ||
| JP2016528891A5 (OSRAM) | ||
| JP2016530882A5 (OSRAM) | ||
| JP2016522817A5 (OSRAM) | ||
| RU2016130110A (ru) | Способы хирургической обработки путем резания и сшивания скобками | |
| JP2012050438A5 (OSRAM) | ||
| JP2012136542A5 (OSRAM) | ||
| RU2016129725A (ru) | Модуляция экспрессии ангиопоэтин-подобного белка 3 | |
| JP2010507579A5 (OSRAM) | ||
| JP2019088329A5 (OSRAM) | ||
| CN112274647A (zh) | 寡聚物和寡聚物缀合物 | |
| RU2014119787A (ru) | Антисмысловая регуляция экспрессии gccr |